This review examines the impact of "weight-friendly" pharmacotherapies in the management of type 2 diabetes mellitus (T2DM), emphasizing the importance of considering the weight effects of different treatment regimens. It highlights that certain antidiabetic agents, such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors, are associated with weight neutrality or
